2016-003253-15: Influence of a new medicine on cholesterol and other factors after intake of a meal in patients with diabetes |
|
|
| Ongoing | 4 | 20 | Europe | Solution for injection in pre-filled pen, Praluent | Franciscus Gasthui, Franciscus Gasthuis | Diabetes mellitus type 2 Diabetes mellitus type 2, Diabetes Suikerziekte, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-004794-41: Arterial wall inflammation measured with 18F-FDG PET/CT in patients with statin intolerance before and after treatment with a PCSK-9 inhibitor |
|
|
| Ongoing | 4 | 50 | Europe | Alirocumab, SAR236553 (REGN727), Solution and suspension for suspension for injection in pre-filled syringe, Alirocumab | Academical medical centre, dep of internal medicine, Academical medical centre, department of internal, Sanofi | Patients with CV-risk and statin intolerance due to statin-associated muscle symptoms (SAMS), Patients at cardiovascular risk and statin intolerance due to statin-associated muscle symptoms (SAMS), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-005602-10: Study which will investigate, if the treatment with Inclisiran, Bempedoic acid and monoclonal antibodies Alirocumab or Evolocumab has other than lipid-lowering effects such as change in platelet activity and inflammation markers. |
|
|
| Not yet recruiting | 3 | 60 | Europe | Inclisiran, Nilemdo, Repatha, Rosuvastatin, Atorvastatin, Solution for injection in pre-filled syringe, Film-coated tablet, Leqvio, Nilemdo, Repatha, Rosuvastatin, Atorvastatin | Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB), Verein zur Fördferung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB) | platelet activity and inflammation markers in patients with coronary artery disease, platelet activity and inflammation markers in patients with coronary artery disease, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
GEBI, NCT04613167: Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment |
|
|
| Recruiting | N/A | 70 | Europe | Alirocumab, Evolocumab, Control group | University Medical Centre Ljubljana | Acute Coronary Syndrome, Premature Coronary Heart Disease, Lipoproteinemia, Inflammation, Genetic Polymorphisms | 06/21 | 10/21 | | |
